GlassScriptPhysician profile
Lisa L Marshall
NPI 1477829034
$1,722.88
in general payments reported to CMS, 2019-2025
14 companies · $805 in 2025
The $805 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $180 · 2023: $125 · 2024: $613 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $285.30 | 2025 | Rezdiffra |
| Abbvie INC. | $249.99 | 2024-2025 | |
| Abbott Laboratories | $215.74 | 2023-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Shield Therapeutics INC | $145.93 | 2024 | |
| Biomerieux INC | $142.00 | 2025 | Biofire Respiratory Panel 2.1 |
| Coloplast Corp | $134.45 | 2022 | |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Novo Nordisk INC | $122.90 | 2024 | |
| Genentech USA, INC. | $104.47 | 2025 | Xolair |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.85 | 2024 | |
| Janssen Pharmaceuticals, INC | $46.02 | 2022 | |
| Acadia Pharmaceuticals INC | $23.01 | 2025 | Nuplazid |
| Merck Sharp & Dohme LLC | $14.92 | 2024 | Verquvo |
| Scpharmaceuticals INC. | $14.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.